In the case of subcutaneous glioblastoma, F16–IL2 potentiated the action of temozolomide, leading to complete tumour eradication in all mice 40 days after beginning the treatment, and to the total remission of animals, which remained tumour free for over 160 days (Figure 2A). Here, IL2 is linked to glioblastoma.